No synergistic effect of subtherapeutic doses of donepezil and EVP-6124 in healthy elderly subjects in a scopolamine challenge model

• Published in: Alzheimer's & dementia : translational research & clinical interventions Vol. 5; no. 1; pp. 89 - 98
• Main Authors: Baakman, Anne Catrien, Alvarez-Jimenez, Ricardo, Loewen, Gordon, de Kam, Marieke L., Broekhuizen, Karen, Hilt, Dana C., Groeneveld, Geert Jan
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 2019; John Wiley & Sons, Inc; Elsevier; Wiley
• Subjects: Agonists; Alpha-7 nicotinic agonist; Alzheimer's disease; Binding sites; Cholinesterase inhibitor; Clinical trials; Cognitive ability; Dementia; Donepezil; Drug dosages; EVP-6124; Older people; Pharmacokinetics; Netherlands; Alpha-7 nicotinic agonist; EVP-6124; Cholinesterase inhibitor; Alzheimer's disease; Donepezil

Donepezil is a widely used cholinesterase inhibitor in the management of Alzheimer's disease. Despite large-scaled evidence for its efficacy, elevated peripheral ACh levels often lead to side effects and are dose limiting. The present exploratory study is designed to determine the potentiation...